Poor
Not Aligned
Patient Risk:
Medium
Summary
Most immunization-related general statements are not directly supported by the provided label excerpts; the prompt also lacks label text for indications, dosing, contraindications, boxed warnings, and many safety specifics. Several claims include details (e.g., live vaccine replication, specific vaccine examples, effects on infection risk, vaccine safety/generalities about inactivated vaccines and boosters, and the absence of conclusive evidence) that are not supported or contradicted by the provided COSENTYX label excerpts.
Category Scores
Accurate Statements
Cosentyx works by blocking the action of interleukin-17A (IL-17A).
Supported by label excerpt 12.1: secukinumab selectively binds to IL-17A and inhibits its interaction with the IL-17 receptor.
Cosentyx may alter a patient's immune response to live vaccines.
Supported by label excerpt 5.7: “COSENTYX may alter a patient's immune response to live vaccines.”
Avoid use of live vaccines in patients treated with COSENTYX unless consistent with label guidance.
Supported by label excerpt 5.7: “Avoid use of live vaccines in patients treated with COSENTYX …”.
Unsupported Statements
Cosentyx (secukinumab) is a biologic medication used to treat psoriasis, psoriatic arthritis, and ankylosing spondylitis.
No provided label text for indications (1 INDICATIONS AND USAGE is empty in the prompt). Cannot be supported from provided excerpts.
Cosentyx is a monoclonal antibody that can affect the immune system in various ways.
Partially aligned with 12.1/5.7, but “various ways” is not specified in provided excerpts; only immune response alteration to live vaccines is explicitly mentioned.
Live vaccines contain weakened or attenuated forms of the virus or bacteria that causes a particular disease.
General description of live vaccines is not stated in the provided label excerpt 5.7.
Live vaccines are designed to stimulate the immune system without causing the disease itself.
General immunology claim not stated in provided label excerpt 5.7.
Some live vaccines, such as oral poliovirus vaccine (OPV) and MMR, contain live, attenuated viruses that can replicate in the body.
Specific vaccine examples and replication details are not included in provided label excerpts.
In theory, Cosentyx could interfere with replication of live viruses, potentially reducing vaccine effectiveness.
Provided label excerpt 5.7 does not mention interference with viral replication or vaccine effectiveness outcomes.
CDC guidelines state that live vaccines should be avoided in individuals taking immunosuppressive therapy, including biologic agents, unless benefits outweigh risks.
CDC guidance is not part of the provided FDA label excerpts; label text provided does not contain this statement or any “benefits outweigh risks” language.
American Academy of Dermatology guidance states that patients taking biologic agents, including secukinumab (Cosentyx), should avoid live vaccines unless benefits outweigh risks.
Professional society guidance is not part of the provided FDA label excerpts; label excerpt 5.7 only says to avoid use of live vaccines in patients treated with COSENTYX.
Inactivated vaccines, such as flu vaccine and HPV vaccine, do not contain live viruses.
Not addressed in provided label excerpt 5.7.
Inactivated vaccines are generally safe to administer to individuals taking Cosentyx.
The provided label excerpt 5.7 does not explicitly discuss inactivated vaccines or safety in Cosentyx-treated patients.
Booster shots are typically inactivated vaccines.
Not addressed in provided label excerpts.
Booster shots (typically inactivated vaccines) can be administered to individuals taking Cosentyx.
Not addressed in provided label excerpt 5.7.
There is no conclusive evidence that Cosentyx affects the efficacy of live vaccines.
Not stated in provided label excerpt 5.7 or 12.1.
It is recommended to consult a doctor to weigh benefits and risks if a live vaccine is needed while taking Cosentyx.
Provided label excerpt 5.7 says to “Avoid use of live vaccines in patients treated with COSENTYX” and does not provide a benefits/risks weighing recommendation.
It is not recommended to get a live vaccine if a person is taking Cosentyx unless benefits of vaccination outweigh risks.
The provided label excerpt 5.7 does not include the conditional “unless benefits outweigh risks” phrasing.
Potential risks of administering live vaccines after Cosentyx include increased risk of infection.
Not stated in provided label excerpt 5.7.
Potential risks of administering live vaccines after Cosentyx include other adverse effects.
Not stated in provided label excerpt 5.7.
The decision to administer live vaccines after Cosentyx depends on the type of vaccine and the individual's overall health and potential risks.
Not specified in the provided label excerpt 5.7.
Contradictions
Low
AI Statement
It is not recommended to get a live vaccine if a person is taking Cosentyx unless benefits of vaccination outweigh risks.
Label Reference
Label excerpt 5.7: “Avoid use of live vaccines in patients treated with COSENTYX …” (no benefits-over-risks exception shown in provided text).
Important Omissions
Indications/usage details for psoriasis, psoriatic arthritis, and ankylosing spondylitis (section 1 INDICATIONS AND USAGE content is not provided).
Importance:
Moderate
Dosing and administration instructions (section content not provided).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
The label excerpt explicitly instructs to avoid live vaccines in patients treated with COSENTYX; the AI response adds conditional language (“unless benefits outweigh risks”) and claims about reduced efficacy and increased infection risk that are not supported by the provided excerpts. These unsupported additions could mislead interpretation of the label’s immunization warning.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Many immunization-related statements are not supported by the provided FDA label excerpts, and the response introduces conditional exception language and risk claims not present in the label text shown.
Suggested Improvement
Restrict immunization claims to label-supported text: consider completing age-appropriate immunizations prior to starting; note that COSENTYX may alter immune response to live vaccines; avoid use of live vaccines in patients treated with COSENTYX. Remove unsupported general descriptions (e.g., vaccine replication, specific vaccine examples), and remove unsupported assertions about infection risk, reduced efficacy, and conditional “benefits outweigh risks” phrasing unless directly supported by the provided label.